Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799741 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
A Phase 2 study of DENV-3 Controlled Human Infection Model, sponsored by AbViro.
- Active
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 3
- Study locations
NCT06799741: Active Phase 2 study of DENV-3 Controlled Human Infection Model, sponsored by AbViro.
NCT06799741 is a Phase 2 study of DENV-3 Controlled Human Infection Model that is active but no longer recruiting, run by AbViro. The registered enrollment target is 85 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06799741, a Phase 2 study of DENV-3 Controlled Human Infection Model, is active but no longer recruiting, sponsored by AbViro.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
Primary Outcome
Defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AV-1 100 mg
- DRUG AV-1 300 mg
- DRUG AV-1 900 mg
Study Locations (3)
Maryland
- Center for Immunization Research (CIR) JHBSPH - Baltimore
- Center for Immunization Research Inpatient Unit - Baltimore
Vermont
- UVM Larner College of Medicine Department of MMG - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2026-03-14 |
| Phase | Phase 2 |
What the registry record for NCT06799741 still lists
NCT06799741 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower).
The record links to 1 condition, with DENV-3 Controlled Human Infection Model appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06799741 reports a single indexed study location in Maryland, Vermont.
Frequently Asked Questions
What is clinical trial NCT06799741 about?
NCT06799741 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection". The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
What is the current status of trial NCT06799741?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2025-01-07. Estimated completion is 2026-03-14.
What conditions does trial NCT06799741 study?
This clinical trial studies the following conditions: DENV-3 Controlled Human Infection Model.
What interventions are being tested in trial NCT06799741?
The interventions under investigation include: Placebo (DRUG), AV-1 100 mg (DRUG), AV-1 300 mg (DRUG), AV-1 900 mg (DRUG).
Who is sponsoring clinical trial NCT06799741?
This trial is sponsored by AbViro, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799741 being conducted?
This trial has 3 study locations across Maryland, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06799741's enrollment target sits among peer trials
85 820th of 2000 higher than 1,179 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI